Trial
NCT02928445
Long-Term Extension Study of Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: HEADWAY-DLB Extension
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Axovant Sciences Ltd.
Collaborators
—
Condition
Dementia With Lewy Bodies
Intervention
RVT-101 35 mg
Why stopped
Intepirdine did not meet its primary efficacy endpoints in the lead-in study RVT-101-2001.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-04-18